Lytix Biopharma ASA · OSL:LYTIX

Lytix Biopharma ASA — Investor Presentation (August 2013)

11 slides from Lytix Biopharma ASA's investor presentation, August 2013

  1. Slide 1: LTX-109 – improving nature's own defense mechanisms

    …improving nature’s own defense mechanisms LTX-109 August 2013

  2. Slide 2: Lytix Biopharma scientific background

    2 Lytix Biopharma scientific background T=5 minutes LTX-109 (infection) LTX-315 (cancer) Lactoferrin Lactoferricin  The lactoferrin protein is found in milk and is known to have direct anti-microbial activity and cancer immune modulatory effects  Structure-activity-relationship studies have result

  3. Slide 3: Highly efficient peptides

    3 Highly efficient peptides Ultra rapid membrane disruption Time: 0 min 5 min 10 min 20 min  Host defence peptides form the cornerstone of the body’s protection against a broad spectrum of harmful micro-organisms  Some host defence peptides kill micro-organisms by direct disruption of the cell mem

  4. Slide 4: Significant commercial potential for LTX-109

    4 Significant commercial potential for LTX-109  Global sales of topical antibacterials estimated to USD  Bacterial resistance to antibiotics is a global and 982m in 20101 (primarily Bactroban and Fucidin) increasing problem  Main product in market, Mupirocin, is used for skin  Incidence of MRSA

  5. Slide 5: LTX-109 is a well-documented drug candidate

    5 LTX-109 is a well-documented drug candidate  Fast acting, bactericidal antimicrobial drug  Broad spectrum of activity  Low propensity for resistance development  Effective against multi-drug resistant bacteria  Effective against biofilms

  6. Slide 6: LTX-109 kills MRSA better than Gold Standard drugs

    6 In-vivo animal studies: LTX-109 kills MRSA better than Gold Standard drugs Untreated Placebo 1% Altabax 2% Fusidic /Altargo Acid 1% Lytixar 2% Lytixar  Murine skin infection model (tape-stripping, ATCC 33591)  Read-out is bacterial growth +9 hours after the first of 3 doses

  7. Slide 7: Project status LTX-109

    7 Project status LTX-109  Phase I in healthy volunteers completed  Phase I/IIa pilot study in Gram+ skin infections completed  Phase I/IIa pilot study nasal decolonisation completed Focus in 2013 and 2014  Phase II PoC in impetigo  Active dialog with potential partners

  8. Slide 8: Impetigo – «milk blotch» in children

    8 Impetigo – «milk blotch» in children  Impetigo – Staphylococcus aureus and Streptococcus pyogenes – Pediatric disease – Incidence in 2-4 years old children – ~3 % UK – 12-25% in warmer humid climates  Medical need – Increasing resistance to excisiting antibiotics (Fucidin and Bactroban) – Conven

  9. Slide 9: Nasal decolonisation

    9 Nasal decolonisation  Medical need – Staphylococcus aureus are prevalent colonisers and the most common cause of hospital infections – MRSA (methicillin-resistant S. aureus) has become endemic in health care institutions worldwide, with up to 70% of invasive S. aureus infections having resistance

  10. Slide 10: LTX-109 development milestones

    10 LTX-109 development milestones  Phase II Proof of Concept study in impetigo is ongoing. Results expected first half of 2014  Discussions with potential partners in the area of dermatology and topical infections are ongoing  Effective killing of bacteria in the nose in a Phase I/IIa study. Resu

  11. Slide 11: Lytix Biopharma AS - www.lytixbiopharma.com

    Lytix Biopharma AS - www.lytixbiopharma.com

Lytix Biopharma — Investor Presentation (August 2013) on 6ix